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Abstract 
The human papillomavirus (HPV) is one of the most common sexually transmitted infections (STI) in the 
world and it is associated with cervical cancer. The development of a prophylactic HPV vaccine has 
proven effective in clinical trials and it is now available to the public. The HPV vaccine represents a 
viable prevention strategy against cervical cancer. However, parental preferences, perceptions, and 
willingness to use the HPV vaccine are crucial, and if not assessed accurately, may threaten the successful 
implementation of a broad HPV vaccination program. This pilot study explored the views of 60 adult, 
Mexican women, all of who were mothers of female children between the ages of ten to 14 years old on 
the following four areas of interest: HPV knowledge; HPV vaccine knowledge and attitudes; barriers to 
HPV vaccine use; and potential uses and side effects of the HPV vaccine. Only 7% of respondents knew 
that HPV was a virus or STI. Eighty-six percent had not heard of the HPV vaccine, but 62% felt that the 
HPV vaccine would prevent HPV infection. However, 38% said the church would not approve of the 
HPV vaccine use for 10-14-year-old girls. Twenty-seven percent thought that promiscuous behavior 
would increase following HPV vaccination. Overall, respondents had very little knowledge of the HPV 
vaccine, were willing to be vaccinated themselves (83%), but were lesser willing to vaccinate their 
daughters (63%). Ultimately, understanding the beliefs about and identifying the barriers of HPV vaccine 
use will influence the effectiveness of the vaccine and its potential impact in reducing cervical cancer 
incidence rates worldwide. 
 
© 2006 Californian Journal of Health Promotion. All rights reserved. 




The human papillomavirus (HPV), a ubiquitous 
sexually transmitted virus is widely recognized 
as the most common sexually transmitted 
infection (STI) and cause of genital warts in the 
world (Rathus, Nevid & Ficher-Rathus, 2002). 
In the US alone, there are almost 20 million total 
cases of HPV with approximately 5.5 million 
new cases of HPV infections reported each year 
(Davis, Dickman, Ferris, & Dias, 2004). Genital 
HPV infection can cause genital warts and 
cervical cell abnormalities that produce 
abnormal Pap tests. Additionally, it is associated 
with various types of anogenital cancers, the 
most important of which is cancer of the cervix. 
While rates of HPV are high among all age 
groups, the highest rates of HPV infections are 
seen in women 18-28 years old (Slomovitz et al., 
2006). 
Most genital HPV infections do not cause 
disease, but instead remain asymptomatic and 
clear up on their own without treatment, usually 
within one year. However, several 
epidemiological studies have shown that 
persistent infections with certain types of HPV 
are a necessary risk factor for the development 
of invasive cervical cancer (Bosch & Munoz, 
2002; Munoz et al., 2003; Kjaer et al., 2002). 
Based on such studies, genital HPV types have 
been largely classified into two groups; the high-
risk HPV types (mainly HPV 16 and 18) and the 
low-risk HPV types (mainly HPV 6 and 11), 
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reflecting their potential risk to induce invasive 
cancer. The high- risk types are widely 
acknowledged to be the cause of preinvasive 
cervical disease (i.e., cervical dysplasia or 
cervical intraepithelial neoplasia) and invasive 
cervical cancer (Walboomers et al., 1999).  
Currently, there is no cure for HPV infection; 
therefore, once infected a person is infected for 
life. Prevention of HPV has been largely limited 
to intervention strategies promoting abstinence, 
monogamous sexual relations between 
uninfected individuals, and condom utilization 
during sexual encounters (Davis et al., 2004). 
The recent development of a prophylactic HPV 
vaccine with proven effectiveness in clinical 
trials, has given hope of reducing incidence of 
HPV and cervical cancer worldwide.   
 
Koutsky and colleagues (2002) provided 
evidence of a highly efficacious vaccine against 
HPV 16 infection. In a three-dose regimen of the 
HPV-16 vaccine, incidence of both HPV 16 
infection and HPV 16-related cervical intra-
epithelial neoplasia were reduced. Additionally, 
the incidence of persistent HPV 16 infection was 
0 per 100 woman-years at risk in the vaccine 
group, compared to 3.8 per 100 woman-years at 
risk in the placebo group.   
 
Furthermore, Villa and colleagues (2005) have 
demonstrated the effectiveness of a quadrivalent 
HPV (type 6, 11, 16, and 18) L1 VLP vaccine. 
In an efficacy trial of this quadrivalent HPV 
vaccine, combined incidence of persistent HPV 
6, 11, 16, or 18 infections and their associated 
genital disease was reduced by 90% in women 
in the vaccine group, compared to those 
assigned to the placebo group. The proven 
effectiveness of the HPV vaccines in clinical 
trials to date suggests that HPV vaccination may 
represent a viable preventive strategy in the fight 
against cervical cancer. 
 
However, while a vaccine that prevents HPV 
and cervical cancer has clear advantages, there 
are potential risks and adverse effects associated 
with vaccines, in addition to social and personal 
barriers that need to be overcome, if the 
population at large is to accept and use the HPV 
vaccine.  Parental preferences and perceptions of 
the HPV vaccine are crucial, and if not assessed 
accurately, may threaten the successful 
implementation of a widely encompassing 
vaccination program. 
 
Therefore, the purpose of this pilot study was 
two-prong: (1) assess the willingness of women, 
residing in the border city of Ciudad Juárez, 
Mexico, to use the HPV vaccine; evaluate their 
perceptions about the HPV vaccine, especially 
as it pertained to use with their 10-14-year-old 
daughters; and determine potential barriers to 
vaccine acceptance and compliance, and (2) use 
the respondent responses to develop appropriate 
research questions for the main study. This pilot 
research project represents a preliminary foray 
in our understanding of HPV vaccine acceptance 
and perceptions among Mexican women 
residing in a metropolitan US-México border 
city. This topic has not been previously 




The present study was conducted in Ciudad 
Juárez, México. Ciudad Juárez stands on the Rio 
Grande (Río Bravo del Norte), across the US 
border from its sister cities of El Paso, Texas 
and Las Cruces, New Mexico. The three cities 
form a bi-national metropolitan area of 
approximately 2.5 million people, divided by the 
Rio Grande, making it the largest bi-national 
metropolitan area on the US-Mexico border. 
Ciudad Juárez is a growing industrial city in the 
state of Chihuahua and represents the fifth 
largest city in México with a population of 
approximately 1.4 million inhabitants, 58% of 
whom are reported to be women (INEGI, 2000). 
 
Survey Respondents 
A cross sectional descriptive pilot study was 
conducted to examine women’s HPV infection 
knowledge and HPV vaccine acceptance in 
Ciudad Juárez, Mexico. After approval was 
received from the institutional review boards at 
New Mexico State University and Hospital de la 
Familia, patients were randomly selected to 
complete a survey on HPV knowledge and 
attitudes towards use of an HPV vaccine. The 
sampling frame consisted of approximately 180 
women with female children between the ages of 
10-14 years old; of whom, every third of three 
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Results were systematically selected for inclusion in the 
study. Respondent recruitment occurred during 
regularly scheduled obstetrics and gynecology 
visits to Hospital de la Familia during the 
months of January through March 2006. During 
the visit, potential respondents were approached 
by a social worker to determine their willingness 
to take part in the survey. Only four prospective 
respondents declined to complete the survey; 
with three women citing time restraints and the 
fourth one expressing uneasiness and 
embarrassment over the topic. 
Sociodemographic Characteristics 
The survey sample was composed of 60 adult 
women, ages 24 to 52 with a mean age of 30.2 
years. The majority, 62% were married (n=37) 
with the remaining 13% being divorced/ 
separated, 12% living with an intimate partner, 
10% single, and 3% widowed.  All respondents 
were currently living in Ciudad Juárez and had 
lived in the city for an average of 27.8 years. 
The majority, 95% of respondents had been at 
their current Ciudad Juárez home for twelve or 
more months (n=56).  
 The study respondents were assured of 
anonymity and confidentiality and were 
requested to complete a 25-item, multiple choice 
questionnaire. The questionnaire was originally 
adapted from a previous study examining 
barriers to Pap smear screening practices among 
Hispanic women (Pinzon-Perez et al., 2005). 
The first part of the questionnaire collected 
sociodemographic information. The second part 
assessed their knowledge concerning HPV 
infections and determined their degree of 
acceptance of an HPV vaccine, both for 
themselves and their 10-14-year-old daughters. 
Most respondents (67%) self identified as a 
homemaker (n=40) and had on average, 7.7 
years of schooling. The mean weekly family 
income for respondent families was 1,346 pesos 
(approximately $122 US dollars). This income 
supported households of four individuals in the 
majority of cases (73%). However, for 22% of 
the respondents, their family income supported 
on average seven individuals, and only 5% 




Demographic information (N = 60 respondents) 
 
Characteristics N (%) Mean + SD 
Median age, years 39 40.2+11.4 
Sex   
 Female 60 (100)  
Race   
 Hispanic 60 (100)  
Median family weekly income, pesos 1,000  
Education, years completed 8 7.7+3.2 
Marital status   
 Married 37 (61.7)  
 Divorced/separated 8 (13.3)  
 Widowed 2 (3.3)  
 Never been married 0 (0.0)  
 Living with intimate partner 7 (11.7)  










It is worthy to note that only two of the 
respondents self reported knowing very much 
about HPV. Whereas the remaining respondents 
were equally divided between self-reporting 
knowing “a little” about HPV (n=29), and the 
other half as knowing “very little or nothing at 
all” (n=29). Only a few identified specifically 
what they knew about HPV. Of those, merely 
7% knew that HPV was a virus or STI and that it 
was transmitted during sexual intercourse with a 
man.  Yet, eighty-six percent knew that HPV 
somehow hurts a woman’s body. Of the few 
respondents (n=20) who described how HPV 
hurts women, 85% stated that the virus generally 
harms the body, while only 15% stated that HPV 
causes cervical cancer. Interestingly, an equal 
proportion of the respondents thought that HPV 
harmed women more than men (33%); harmed 
men more than women (33%); or thought HPV 
affected both women and men equally (33%).   
 
HPV Vaccine Knowledge & Attitudes 
Eighty-six percent of the women respondents 
had not heard of the HPV vaccine (n = 50). 
However, 63% of all respondents stated that 
they know advantages of being HPV vaccinated 
and identified four potential benefits of the HPV 
vaccine. The largest number of respondents, 
62% felt that the HPV vaccine would prevent 
HPV infection. Nine percent felt that if 
vaccinated they would feel less worried, 8% 
stated that the vaccine would protect them 
against the virus, and another 8% declared that if 
vaccinated they would live longer and healthier 
lives. Only 4% thought there were no 
advantages to the HPV vaccine, while 9% did 
not know of any possible advantages. 
 
By comparison, when the respondents were 
conversely asked if they knew of any 
disadvantages to HPV vaccination, 83% stated 
either “no” or “do not know” about any 
disadvantages of the HPV vaccine and the 
remaining 17% stated that they knew about HPV 
vaccine disadvantages. When this last subset of 
respondents was asked for specific 
disadvantages, 7% felt that the HPV vaccine 
may influence women to stop getting Pap tests; 
4% stated that the vaccine had not yet been 
approved or distributed; 4% stated that the 
vaccine may not work; and 2% stated it would 
increase promiscuity among women. 
 
The majority of respondents (83%) stated that 
they would be willing to be immunized with an 
HPV vaccine (n=49). By comparison, 7% said 
no to HPV immunization; 2% said maybe; and, 
8% said they did not know whether they would 












Comparison of the willingness of mothers to use the HPV vaccine for themselves as 
opposed to their daughters 
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Reasons for vaccine use included respondents 
identifying HPV immunization as critical to 
disease prevention and as essential to an 
individual’s good health. In so far as identifying 
reasons for not using the HPV vaccine were 
concerned, they mainly centered on the issues of 
potential religious objections, socio-cultural 
beliefs, and fear of adverse effects of the HPV 
vaccine. 
 
When asked to conjecture about a woman’s 
feelings when receiving the HPV vaccine, 41% 
of the respondents felt that the woman would be 
embarrassed or ashamed (n=24), 22% thought 
the woman would feel good about herself 
because she would be protected against HPV, 
16% thought she would feel scared or bad, 12% 
thought she would feel normal or nothing out of 
the ordinary, and 9% did not know. 
 
Respondents were asked about their feelings and 
possible intended behaviors regarding HPV 
immunization of (their) 10 to 14 year-old 
daughters. Sixty-three percent stated that they 
would immunize their girls (n=38), while 25% 
said no to HPV immunization, 1% said maybe, 
and the remaining 11% were undecided (Figure 
1). The most common response in favor of the 
HPV vaccine use among 10-14-year-old girls 
was expressed by 68% of the respondents, who 
stated that it would protect and prevent disease 
(n=28). Additionally, 15% stated that they 
would use the vaccine if it was recommended by 
a physician. 
 
By comparison, of those respondents who were 
against use of the HPV vaccine (n=15), 33% 
said their girls were too young, another 33% said 
their girls do not need the vaccine, 26% said 
they need more information and education about 
the HPV vaccine, and 7% said they did not 
know.  Interestingly, the majority of the mothers 
(58%) felt that HPV immunization would not 
lead their daughters into earlier initiation of 
sexual activity (n=35), while 27% thought it 
could, and the remaining 15% were not sure or 
did not know. Additionally, the majority of the 
mother respondents (75%) felt that vaccination 
of their 10- or 14-year-old girls could not wait 
(n=45), while 19% felt that HPV vaccination 
could wait until their daughters were at least 18 
years old. 
HPV Vaccine & Potential Barriers 
Respondents were asked to identify attitudes and 
potential barriers to HPV vaccine use. When 
asked about the church’s approval for use of the 
HPV vaccine with 10 to 14 year-old girls, 38% 
said the church would not approve (n=23), an 
equal number (38%) said the church would 
approve, 20% did not know (n=11), and 5% said 
that the church has nothing to do with it. For the 
23 respondents who offered a positive opinion, 
the majority (64%) thought that the church 
would be in favor of the HPV vaccine for young 
girls because the church wants what is best for 
the people and another 31% noted that  in recent 
years, the church has becoming more tolerant 
and accepting in it’s views.  
 
Other opinions reflected a negative perception 
regarding the church’s attitude. Specifically, of 
the 23 respondents who thought the church 
would not approve of the HPV vaccine use with 
young girls, 47% offered that the church’s 
beliefs conflict with medicine and science, 25% 
said the church does not approve of premarital 
sex, 22% said the church does not want the HPV 
vaccine used by its followers because it may 
increase promiscuity, and 9% said that 10-14 
year old children are too young to receive such a 
vaccine. 
 
On the question of how they would respond, if 
the church were to oppose use of the HPV 
vaccine, 34% said that they would support the 
church’s decision (n=20), while 59% said they 
would be against the church’s decision. Of the 
20 respondents who offered an opinion in 
support of a decision by the church not to use 
the HPV vaccine, 66% said they would do so 
because the vaccine is not beneficial and 33% 
offered that there are other ways to protect 
yourself and children against HPV. By 
comparison, the reason given most often by the 
36 respondents for refusing to follow a possible 
anti-vaccine use mandate by the church was 
identified by 56% of the respondents to be the 
fact that the HPV vaccine was best for their 
child’s health (n=20), with another 24% stating 
that it saves lives and prevents disease. 
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Perceptions of the Potential Uses & Side 
Effects of the HPV Vaccine 
Perceptions of the potential uses and side effects 
of the HPV vaccine were also identified. 
Surprisingly, 55% of the respondents thought 
that women who were vaccinated for HPV 
would not feel protected from cervical cancer 
(n=33) (Figure 2), whereas only 29% though 
that vaccinated women would believe that they 
were protected against the disease. Similarly, the 
majority (68%) thought that vaccinated women 
would not believe that the HPV vaccine would 
protect them against other STIs (n=41), while 
20% thought that it would.  
 
When asked about a woman’s potential increase 
in sexually promiscuous behavior (including a 
potential increase in the number of sexual 
partners and an increase in unsafe sex practices, 
such as lack of condom utilization) following 
HPV vaccination, 27% thought that promiscuous 
behavior would increase (n=16) (Figure 2), and 
68% thought that it would not. Related, only 
14% of the respondents felt that STIs served as a 
deterrent or punishment for promiscuous people 
(n=8), while the remaining 86% felt that it does 
not.  
 
The respondents were particularly concerned 
about the possible side effects of the HPV 
vaccine. The main concern expressed by 19 of 
the respondents, centered on their fear of 
potentially contracting an HPV infection and 
developing cervical cancer as a consequence of 
receiving the HPV vaccine (32%) (Figure 2). On 
the other hand, 53% thought that the vaccine 
was safe and believed that its use would help 
reduce their likelihood of getting cervical cancer 
(n=32). When respondents were asked if they 
trusted public health officials, the medical 
establishment, and pharmaceutical companies 
about the efficacy of the HPV vaccine, 66% said 



































eived barriers to HPV vaccine use* 
ant differences in the patterns of acceptance of the HPV vaccine when 
arital status, number of children, educational level, income, and other 
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Discussion 
For an HPV vaccination program to be 
successful, the vaccine must not only be 
effective in preventing disease, but it must also 
be widely accepted and used by the public. In 
the present study, there was a disappointingly 
low level of knowledge and understanding of 
HPV and the HPV vaccine by the majority of the 
respondents (96% and 86%, respectively). On 
the other hand, and despite their admittedly 
limited knowledge, the majority of the 
respondents expressed a general willingness to 
either be vaccinated themselves (82%) or 
vaccinate their daughters (63%) with the HPV 
vaccine. 
 
While studies examining respondent perceptions 
with regard to HPV vaccination are limited, 
several researchers have found that health 
beliefs like concerns about the efficacy of the 
vaccine, uncertainty about vaccine safety, fear of 
potential vaccine side effects and religious 
objections were generally associated with 
vaccination programs (Taylor et al., 2002; 
Zimet, Liau & Fortenberry, 1997). Likewise, in 
this study cohort, the reasons for not accepting 
the HPV vaccine included lack of efficacy (4%), 
fear of potential increased promiscuous behavior 
by vaccinated female teens and women (23%), 
religious beliefs (34%), and adverse effects, that 
included a surprisingly 32% of the respondents 
fearing that if vaccinated they may contract an 
active HPV infection and end up developing 
instead of averting cervical cancer in the future. 
 
It has been widely stated in the literature that 
increased knowledge and awareness of a 
particular disease and its concomitant vaccine 
have proven to be important determinants of 
people’s health beliefs and practices 
(Bodenheimer, Fulton & Kramer, 1986). Thus, 
given the low level of knowledge and 
understanding of HPV and the HPV vaccine by 
the overwhelming majority of our respondents, it 
is suggested that an HPV public health campaign 
and educational intervention aimed at our female 
population of interest would increase their 
acceptance of the HPV vaccine for themselves 
and especially for their young daughters.  
 
In fact, Davis and colleagues (2004) studied a 
similar population of respondents (mothers of 
young children ages 10-15 years old) and they 
discovered that initially only 55% of the mothers 
were willing to accept the HPV vaccine for their 
children. However, after an educational 
intervention, the number of mothers willing to 
have their children vaccinated increased to 75%. 
Similarly, a study conducted by Lazcano-Ponce 
and colleagues (2001) in Cuernavaca, México, 
demonstrated that upon receiving an explanation 
on how possibly an HPV vaccine may prevent 
cervical cancer in their daughters, 84% of the 
women respondents said that they would allow 
their teenage daughters to be vaccinated. These 
studies emphasize the important role that public 
health educational interventions could play in 
preparing our population for the wide 
implementation and acceptance of the HPV 
vaccine. 
 
In this study, potential religious objections, 
socio-cultural beliefs, and adverse effects of the 
HPV vaccine were identified as the main 
limiting factors to its wider acceptance and 
usage. Similarly, Bodenheimer and colleagues 
(1986) found the main factor determining 
respondents’ willingness to be vaccinated with 
the hepatitis B vaccine was their fear of 
contracting the actual disease. Yet other 
researchers have shown that religious objections 
and socio-cultural beliefs, especially against 
STIs are a major determinant of whether 
vaccines against these infections are accepted by 
the public (Jackson et al., 1995; Zimet et al., 
1997). If in fact that’s the case, an STI vaccine 
such as the HPV vaccine, in a predominantly 
Catholic country like México, may be met with 
unique barriers and unexpected resistance. 
 
Resistance to an HPV vaccination program may 
arise because in Latin America, there is a well-
known socio-cultural stigma associated with 
sexual behavior and STIs. This is especially true 
in México, where information and education 
pertaining to sexual behaviors, practices, and 
STIs are not widely acknowledged or made 
readily available (Blanc & Way, 1998). 
 
It is worthy to note that many of the potential 
barriers to the HPV vaccine will be unlike the 
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ones encountered in other vaccination programs. 
One such unique barrier reported in this study 
was parental apprehension to vaccinate their 10-
14-year-old daughters against a STI (i.e., HPV). 
Therefore, even though 83% of the mother 
respondents were willing to receive the HPV 
vaccine for themselves, only 63% expressed a 
similar willingness to vaccinate their young 
daughters. This substantial difference in HPV 
vaccine acceptance was mainly attributed to the 
maternal belief that their daughters were not 
sexually active and therefore, did not need to be 
vaccinate at such a young age (25%). This belief 
appears to be quite prevalent among Mexican 
parents despite well documented evidence that 
points to a trend of sexual initiation at younger 
ages among their adolescent children (Pisani et 
al., 2000). Thus, the major question for many 
parents would be whether vaccination of their 
daughters for HPV might be perceived as 
condoning sexual intercourse at a younger age. 
 
Another distinct barrier to the HPV vaccine 
especially among the heavily Catholic Hispanic 
populations examined by this study appeared to 
be whether or not the church would endorse the 
use of the HPV vaccine. Given the previous 
stands of the Catholic church against any and all 
premarital sexual relations and the potential 
fears shared by some within the Catholic 
community in regard to the HPV vaccine either 
encouraging its young followers to engage in 
sexual relations early on in their adolescent lives 
and before marriage or providing safe heaven to 
promiscuity; it will be interesting to see on 
which side of the HPV vaccine issue, the official 
Catholic church position would weigh in and 
what kind of impact on vaccine acceptance this 
decision would have on its followers.  
 
Conclusions 
Hence, even though the potential to reduce 
cervical cancer mortality through the 
introduction of a viable HPV vaccine is an 
exciting and promising idea, currently approved 
for use in the US by the Food and Drug 
Administration (Food & Drug Administration 
News, 2006), many questions and obstacles still 
remain before its successful implementation on a 
grand international scale. It is quite evident from 
this study that the effectiveness of such a 
vaccine on the US-México border will largely 
depend on the willingness of the mainly 
Hispanic population of interest to accept and use 
the HPV vaccine. However, experience with 
existing vaccines has demonstrated reluctance to 
accept immunization, even among those 
populations at risk (Zimet, Liau & Fortenberry, 
1997). Thus, future public health educational 
initiatives not only need to increase awareness 
and understanding of HPV and the HPV vaccine 
among this vulnerable and yet uninformed 
population but must also specifically address 
many of the barriers cited by the women in this 
study through the design and implementation of 
culturally appropriate interventions. 
 
Finally, there were several limitations to this 
study. First, this was a pilot evaluation and our 
sample size was limited (N=60), making it 
difficult to make generalized inferences to the 
population at large. Second, the instrument used 
had not been rigorously tested for validity and 
reliability. Third, the instrument most likely did 
not address all the potential barriers of why 
women may choose not to use the HPV vaccine 
for themselves and their young daughters. 
Nonetheless, this study does provide much 
useful insight into potentially unique barriers 
faced by women residing on the US-México 
border and offers promise and direction to future 
public health initiatives. 
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